Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403:1791–807.

Article  PubMed  CAS  Google Scholar 

Stephens DM, Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138:1099–109.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhong G, Kong R, Feng S, Wang C, Hao Q, Xie W, et al. Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting. J Hematol Oncol. 2024;17:14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021;18:401–17.

Article  PubMed  PubMed Central  Google Scholar 

Kozicka Z, Thoma NH. Haven’t got a glue: Protein surface variation for the design of molecular glue degraders. Cell Chem Biol. 2021;28:1032–47.

Article  PubMed  CAS  Google Scholar 

Goldhirsh G, Kravtsova-Ivantsiv Y, Satish G, Ziv T, Brik A, Ciechanover A. A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-kappaB1 p105 to p50: a potential for a tumor-suppressive PROTAC. Proc Natl Acad Sci USA. 2021;118:e2117254118.

Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN. Br J Haematol. 2014;164:811–21.

Article  PubMed  CAS  Google Scholar 

Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5.

Article  PubMed  Google Scholar 

Drula R, Iluta S, Gulei D, Iuga C, Dima D, Ghiaur G, et al. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev. 2022;56:100971.

Article  PubMed  CAS  Google Scholar 

Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–9.

Article  PubMed  CAS  Google Scholar 

Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016;532:127–30.

Article  PubMed  CAS  Google Scholar 

Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. Expert Opin Drug Discov. 2019;14:1237–53.

Article  PubMed  CAS  Google Scholar 

Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.

Article  PubMed  CAS  Google Scholar 

Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–22.

Article  PubMed  CAS  Google Scholar 

Martinez-Valbuena I, Lee S, Santamaria E, Irigoyen JF, Forrest S, Li J, et al. 4R-Tau seeding activity unravels molecular subtypes in patients with progressive supranuclear Palsy. bioRxiv. 2023.

Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:77.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen X, Lu T, Cai Y, Han Y, Ding M, Chu Y, et al. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway. Cell Mol Biol Lett. 2023;28:32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem. 2009;284:32384–94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen L, Li C, Pan Y, Chen J. Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol. 2005;25:6509–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211:605–12.

Article  PubMed  PubMed Central  Google Scholar 

Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science. 2003;302:1581–4.

Article  PubMed  CAS  Google Scholar 

Schulze-Luehrmann J, Ghosh S. Antigen-receptor signaling to nuclear factor kappa B. Immunity. 2006;25:701–15.

Article  PubMed  CAS  Google Scholar 

Bidere N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, et al. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature. 2009;458:92–96.

Article  PubMed  CAS  Google Scholar 

Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13.

Article  PubMed  Google Scholar 

Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature. 1998;396:590–4.

Article  PubMed  CAS  Google Scholar 

Gehring T, Erdmann T, Rahm M, Grass C, Flatley A, O’Neill TJ, et al. MALT1 phosphorylation controls activation of T lymphocytes and survival of ABC-DLBCL tumor cells. Cell Rep. 2019;29:873–88.e810.

Article  PubMed  CAS  Google Scholar 

Carvalho G, Le Guelte A, Demian C, Vazquez A, Gavard J, Bidère N. Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation. J Cell Sci. 2010;123:2375–80.

Article  PubMed  CAS  Google Scholar 

Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2:a000109.

Article  PubMed  PubMed Central  Google Scholar 

Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, et al. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci USA. 2015;112:E7230–38.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.

Article  PubMed  PubMed Central